Ellsworth Michael A, Fairbanks Kris K, Behan Stephen, Jackson James A, Goodyear Mark, Oien Nancee L, Meinert Todd R, Leyh Randy D
Pfizer Global Manufacturing, 601 West Cornhusker Highway, Lincoln, Nebraska 68521, USA.
Vet Ther. 2006 Fall;7(3):295-304.
This study demonstrated that the bovine viral diarrhea virus (BVDV; types 1 and 2) fractions of a multivalent vaccine protected pregnant heifers and their fetuses at 149 to 217 days of gestation against exposure to calves persistently infected with BVDV type 2a. Eighty percent (eight of 10) of the control heifers were viremic at least 1 day following challenge, whereas all (20 of 20) BVDV-vaccinated heifers were virus isolation-negative on all postchallenge assessment days. Ninety percent (nine of 10) of the calves born to control heifers but only 5% (one of 20) of calves born to BVDV-vaccinated heifers seroconverted to BVDV type 2 before ingesting colostrum. One calf born to a control heifer was persistently infected. No calves from BVDV-vaccinated heifers were persistently infected.
本研究表明,一种多价疫苗中的牛病毒性腹泻病毒(BVDV;1型和2型)组分可在妊娠149至217天保护怀孕的小母牛及其胎儿,使其免受暴露于持续感染2a型BVDV的犊牛的影响。80%(10头中的8头)对照小母牛在攻毒后至少1天出现病毒血症,而所有(20头中的20头)接种BVDV疫苗的小母牛在攻毒后的所有评估日病毒分离均为阴性。对照小母牛所生犊牛中有90%(10头中的9头)在摄入初乳前血清转化为2型BVDV,但接种BVDV疫苗的小母牛所生犊牛中只有5%(20头中的1头)血清转化。对照小母牛所生的一头犊牛被持续感染。接种BVDV疫苗的小母牛所生的犊牛没有一头被持续感染。